title: [Parameters of hemostasis during treatments associating fractionated heparin administered subcutaneously to standard and fractionated heparin administered intravenously in the chronic hemodialysis patient].
abstract: The hemorrhagic risk of an association of fractioned heparin (Fraxiparine) injected intravenously at the dose of 7500 AXaICU or of unfractionned heparin (UFH) injected intravenously at the usual dose used for a priming dose for hemodialysis (3750 +/- 1280 IU + 1000 IU after 2 hours of dialysis) to the subcutaneous administration of a thrombo-embolism preventive dose of Fraxiparine (7500 AXaICU) was evaluated on the modifications of the following hemostasis parameters: thrombin time, Activated Partial Thrombin Time (APTT), prothrombin time, anti Xa activity in 13 uremic patients on hemodialysis. The association of intravenous and subcutaneous Fraxiparine prevents efficiently the clotting of the extracorporeal circulation without inducing a detectable antithrombinic activity. In contrast, the association of I.V. UFH to subcutaneous Fraxiparine induces a significant increase of the thrombin time and of the APTT. This latter is exclusively explained by the activity of UFH. It is concluded that subcutaneous Fraxiparine at the thromboembolism preventive dose can be associated as well to I.V. Fraxiparine as to UFH without increasing the antithrombinic activity of the plasma.
authors.affiliation: Service de Néphrologie, Hémodialyse, CHU Amiens.
authors.forename: P
authors.initials: P
authors.lastname: Morinière
authors.forename: J
authors.initials: J
authors.lastname: Diéval
authors.forename: B
authors.initials: B
authors.lastname: Roussel
authors.forename: S
authors.initials: S
authors.lastname: Gross
authors.forename: B
authors.initials: B
authors.lastname: Bayrou
authors.forename: J
authors.initials: J
authors.lastname: Delobel
authors.forename: A
authors.initials: A
authors.lastname: Fournier
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D015951:Factor Xa / Q000276:immunology; D005260:Female; D006487:Hemostasis; D006493:Heparin / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011516:Prothrombin / Q000032:analysis; D006435:Renal Dialysis; D013918:Thrombin Time
chemical_list: D001323:Autoantibodies; D011516:Prothrombin; D006493:Heparin; D015951:Factor Xa
vernacular_title: Etude des paramètres de l'hémostase au cours de traitements associant l'héparine fractionnée par voie sous-cutanée aux héparines standard et fractionnée par voie intraveineuse chez l'hémodialysé chronique.